Renal transplant recipients have increased mortality rates when compared with the general
population. The new immunosuppressive drugs have improved short-term patient survival …

Background. Polyomavirus-associated nephropathy (PVAN) is an important cause of kidney
graft loss but there is no consensus on its management. This study aimed to systematically …

The present AST‐IDCOP guidelines update information on BK polyomavirus (BKP yV)
infection, replication, and disease, which impact kidney transplantation (KT), but rarely non …

Early detection of polyomavirus BK (BKV) viremia and reduction of immunosuppression is
recommended for preventing polyomavirus-associated nephropathy (Py-VAN), but …

In the last 10 years, better immunosuppression drugs have decreased the rates of acute
rejection in kidney transplantation but have also led to the emergence of polyomavirus …

The human polyomavirus BK (BKV) is linked to two major complications in transplant
recipients, polyomavirus-associated nephropathy (PyVAN)(1, 2, 3, 4) and polyomavirus …

Mycophenolate mofetil (MMF) is one of the most frequently used immunosuppressive drugs
in solid organ transplant recipients. MMF is an inhibitor of inosine‐5′‐monophosphate, and …

There has been a notable rise of BK virus among kidney transplant recipients. Single‐center
reports have identified risk factors for development of BK virus. However, there has not been …

BK polyomavirus (BKPyV) remains a significant challenge after kidney transplantation.
International experts reviewed current evidence and updated recommendations according …

Polyomavirus-associated nephropathy (PVAN) remains an important infectious complication
after renal transplantation, affecting 1–10% of recipients and causing graft loss in …